Young adults with sarcoma face challenges that extend well beyond treatment, and closing gaps in research funding and specialty care could improve outcomes for this population and beyond, according to ...

Early remdesivir treatment was associated with lower graft loss and cardiovascular events in kidney transplant recipients, noted Nitipong Permpalung, MD, MPH.

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at ...

Moving to a subQ formulation makes sense, if you want to be 100% convenient for patients and the centers that treat them, explains Xavier Leleu, MD, PhD.

Alireza Atri introduces mild behavioral impairment as an early-emerging framework for behavioral changes preceding formal dementia diagnosis. Alireza Atri introduces mild behavioral impairment as an ...

Workforce expansion authorized after the 2024 Harlem outbreak remains incomplete, with 35 staff onboard versus a planned 56, leaving gaps in inspection and response throughput. A second lethal cluster ...

In June, Moderna and Merck reported clinical trial follow-up results showing that their combination mRNA cancer vaccine and ...

Mean LDL-C at 6 months was 76.3 vs 85.6 mg/dL, yielding an adjusted difference of −6.62 mg/dL and higher attainment of LDL-C <50 mg/dL. Intervention uptake increased intensive and combination ...

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, and ...

Dermatology offices spend ~13 hours weekly on prior authorizations, file ~39 requests per physician annually, and see roughly one-third denied, creating operational costs and delayed initiation of ...

The FDA's Pharmacy Compounding Advisory Committee met July 23-24 to consider whether 7 unapproved peptides—BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon, and semax—should be added to the agency's ...

Urs Weber, MD, discusses why comprehensive NGS is critical and where community biomarker testing often falls short.